Sumitomo Mitsui Trust Group Inc. Reduces Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sumitomo Mitsui Trust Group Inc. trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.6% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 8,277 shares of the medical equipment provider’s stock after selling 487 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Lantheus were worth $808,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Summit Securities Group LLC purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $37,000. UMB Bank n.a. raised its stake in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock valued at $92,000 after buying an additional 381 shares during the last quarter. Blue Trust Inc. raised its stake in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 633 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after buying an additional 298 shares during the period. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Lantheus in the 4th quarter worth $125,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on LNTH shares. B. Riley lowered their target price on Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a report on Monday, June 23rd. Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Finally, Truist Financial dropped their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus has a consensus rating of “Buy” and a consensus price target of $130.50.

Lantheus Stock Performance

Shares of LNTH opened at $79.21 on Friday. The business has a 50-day simple moving average of $82.57 and a two-hundred day simple moving average of $90.24. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89. The stock has a market cap of $5.48 billion, a price-to-earnings ratio of 22.50 and a beta of 0.12.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million during the quarter, compared to analysts’ expectations of $377.37 million. During the same period in the prior year, the company posted $1.69 earnings per share. The company’s revenue was up .8% compared to the same quarter last year. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the company’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares of the company’s stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.50% of the stock is owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.